Breast cancer: Updates and advances in 2016

Sara B. Giordano*, William Gradishar

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Purpose of review Approximately 1 in 8 US women (12%) will develop invasive breast cancer over the course of her lifetime. In 2016, an estimated 246,660 new cases of invasive breast cancer are expected to be diagnosed and approximately 40,450 would die as a result of it. The global burden of breast cancer exceeds all other cancers and the incidence is increasing. The heterogeneity of breast cancer makes it a challenging solid tumor to diagnose and treat. This review focuses on the recent advances in breast cancer therapy including hormonal treatment of metastatic breast cancer, targeting cyclin-dependent kinases (CDK) 4/6 in breast cancer, updates in targeting human epidermal growth factor receptor 2 (HER2) positive breast cancer, adaptive randomization trial design and cancer genetic risk assessment. Recent findings Breast cancer is a heterogeneous disease and targeted therapy is improving the outcomes of women. The use of cyclin-dependent kinase inhibitors (CDK) 4/6 have demonstrated a substantial improvement in progression-free survival in the first line setting of metastatic hormone receptor positive breast cancer. And newer agents directed at HER2 continue to revolutionize HER2-positive breast cancer treatment. Summary This review highlights the recent updates in breast cancer treatment, new concepts in clinical trial design and provides a current overview of cancer genetic risk assessment.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalCurrent Opinion in Obstetrics and Gynecology
Issue number1
StatePublished - 2017


  • Breast cancer
  • Cancer genetics
  • Cyclin-dependent kinase
  • HER2
  • Hormone sensitive
  • Metastatic/advanced stage
  • Targeted therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Breast cancer: Updates and advances in 2016'. Together they form a unique fingerprint.

Cite this